NCT07094022Completed
Improvement and Safety of Nutrilite Protein MetX Pro on Weight Management in Overweight Individuals With Dyslipidemia
A Randomized, Double-blind, Placebo-controlled, Single Center Study to Evaluate of the Improvement and Safety of Nutrilite Protein MetX Pro on Weight Management in Overweight Individuals With Dyslipidemia
Source: ClinicalTrials.gov · Last updated 30 Jul 2025
Brief summary (registry, in English)
The goal of this randomized, double-blind, placebo-controlled, single center study is to evaluate the impact of Nutrilite Protein MetX Pro (the study product, a high-protein compound beverages supplemented with multiple plant proteins and apple extracts) on lipid profiles in the blood test in overweight individuals with dyslipidemia. The main question it aims to answer is: \- Does the intake of the study product improve the blood lipid profiles (TC,TG, LDL-C ) in terms of of overweight individuals with dyslipidemia? Researchers will compare the product group to a placebo group to see whether the blood lipid profile is significantly better improved for participants in the product group. Participants will: * take randomly assigned products 16g/each time, twice a day for 4 weeks * make four times site visits, once a week. Blood samples are collected for each visit, and Feces are collected for the first and last site visit.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 66 (actual)
- First submitted
- 22 Jul 2025
- Start date
- Mar 2025
- Primary completion date
- Jun 2025
- Lead sponsor
- Amway (China) R&D Center
- Diseases
- Obesity
- NCT number
- NCT07094022
What you commit to
- Study type: Interventional
- Participants enrolled: 66
- From Mar 2025 to the primary completion date, Jun 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Those who have taken lipid-lowering drugs or the like in the past two weeks, which has affected their judgment of the results.
Other illness
- Pregnant or lactating women, those with allergic constitutions, or those allergic to this test sample.
- Patients with severe diseases of the heart, liver, kidneys and hematopoietic system, as well as those with mental illness.
Other
- Patients with hyperlipidemia.
- The researcher determined that the participant was not suitable for this trial.
Who the study is looking for
- Age: 18-65 years old
- Overweight or obese participants, 40 with a BMI of 24-28 kg/m², and 40 participants with a BMI greater than 28. The percentage of male participants is ≥40%. And the lipid profile with the following characteristics:
- TC (Total Cholesterol): 5.18-6.21 mmol/L;
- TG(Triglyceride): 1.70-2.25 mmol/L;
- LDL-C(Low-Density Lipoprotein Cholesterol): ≥ 3.4 mmol/L;
- Agree to sign the informed consent form.
Age in the registry: 18 years to 65 years · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Jinhua Wenrong Hospital Coordinator of this site? Confirm its status | Jinhua | China | Unknown status |
| Raison Biotech Group Shanghai Lab Coordinator of this site? Confirm its status | Shanghai | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.